Vertex Pharmaceuticals Incorporated (VRTX)’in fiyatı nedir?

Vertex Pharmaceuticals Incorporated (VRTX)’in fiyatı $519.38’dir

Vertex Pharmaceuticals Incorporated (VRTX)’in piyasa değeri nedir?

Vertex Pharmaceuticals Incorporated (VRTX)’in piyasa değeri $131.82B’dir.

Vertex Pharmaceuticals Incorporated (VRTX) Geliri

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Yıl	Gelir	Değiştir
2026 (TTM)	$12.62B	5.19%
2025	$12.00B	8.90%
2024	$11.02B	11.66%
2023	$9.87B	10.51%
2022	$8.93B	17.91%
2021	$7.57B	22.06%
2020	$6.21B	49.07%
2019	$4.16B	36.59%
2018	$3.05B	22.46%
2017	$2.49B	46.20%
2016	$1.70B	64.89%
2015	$1.03B	77.86%
2014	$580.42M	-52.11%
2013	$1.21B	-20.63%
2012	$1.53B	8.25%
2011	$1.41B	883.91%
2010	$143.37M	40.49%
2009	$102.05M	-41.85%
2008	$175.50M	-11.81%
2007	$199.01M	-8.02%
2006	$216.36M	34.47%
2005	$160.89M	56.63%
2004	$102.72M	48.56%
2003	$69.14M	-57.08%
2002	$161.09M	-3.82%
2001	$167.49M	114.38%
2000	$78.13M	0.00%

Yıl

Gelir

Değiştir

2026 (TTM)

$12.62B

5.19%

2025

$12.00B

8.90%

2024

$11.02B

11.66%

2023

$9.87B

10.51%

2022

$8.93B

17.91%

2021

$7.57B

22.06%

2020

$6.21B

49.07%

2019

$4.16B

36.59%

2018

$3.05B

22.46%

2017

$2.49B

46.20%

2016

$1.70B

64.89%

2015

$1.03B

77.86%

2014

$580.42M

-52.11%

2013

$1.21B

-20.63%

2012

$1.53B

8.25%

2011

$1.41B

883.91%

2010

$143.37M

40.49%

2009

$102.05M

-41.85%

2008

$175.50M

-11.81%

2007

$199.01M

-8.02%

2006

$216.36M

34.47%

2005

$160.89M

56.63%

2004

$102.72M

48.56%

2003

$69.14M

-57.08%

2002

$161.09M

-3.82%

2001

$167.49M

114.38%

2000

$78.13M

0.00%

Şirket	Gelir	Gelir Farkı	Ülke
Argenx SE ARGX.US	$6.02B	-52.30%	NL
CSL Limited CSL.AX	$15.74B	24.71%	AU
Moderna, Inc. MRNA.US	$2.23B	-82.35%	US
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$10.11B	-19.91%	BE

Şirket

Gelir

Gelir Farkı

Ülke